Innogenetics sublicenses research use of beta-amyloid biomarker to IBL

By Lisa Kerner

Erie, Pa., April 27 - Innogenetics NV sublicensed from Takeda Pharmaceutical Co. Ltd., Japan, its patent rights for the research market of beta-amyloid kits to Immuno-Biological Laboratories Co., Ltd. (IBL)

Innogenetics and Takeda entered into a worldwide licensing agreement in 2004, giving Innogenetics the right to sublicense the diagnostic and research use of beta-amyloid.

Under the agreement with IBL, Innogenetics will receive a license fee and royalties from IBL.

The abnormal accumulation of the biomarker beta-amyloid protein in the brain is considered a pathological hallmark of Alzheimer's disease, Innogenetics said.

"This first sublicense agreement with IBL reinforces Innogenetics' international position in the field of neurodegenerative biomarkers and is an important step in our beta-amyloid licensing program," Innogenetics chief executive officer Frank Morich said in a news release.

IBL of Gunma, Japan, develops antibodies against proteins related to cancers, inflammation and disorders of the brain and the nervous system.

Gent, Belgium-based Innogenetics is a biopharmaceutical company specializing in diagnostics and therapeutic vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.